Why is Bharat Immunolog falling/rising?

As of 12-Sep, Bharat Immunological & Biological Corporation Ltd is experiencing a decline in its stock price, currently at 22.00, reflecting a decrease of -0.18 or -0.81%. The stock has underperformed its sector today by -1.1%, and it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Additionally, the delivery volume has significantly dropped by -81.27% compared to the 5-day average, indicating falling investor participation. Over the past year, the stock has generated a return of -23.66%, and its long-term fundamentals are weak, with net sales declining at an annual rate of -24.67% and a high debt-to-EBITDA ratio of -1.00 times. The company has not declared results in the last six months, contributing to its risky trading status.
In the broader market context, the stock's recent performance contrasts sharply with the benchmark, as it has underperformed the Sensex, which has gained +1.48% over the past week. While Bharat Immunological has shown a slight positive return of +2.23% over the past month, its year-to-date performance remains poor at -7.52%, compared to the Sensex's +4.82%. The consistent underperformance against the benchmark over the last three years, coupled with negative financial results, suggests a lack of investor confidence and a challenging outlook for the company.